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We present a case of a 71-year-old male with recently 
diagnosed, limited-stage, small cell lung cancer status 
post chemotherapy and radiation, who presented 
with numbness of his hands, feet, and the area sur-
rounding his mouth. The patient had undergone three 
cycles of chemotherapy and radiation with cisplatin 
etoposide, with the last cycle occurring one week prior 
to admission. In addition to the above symptoms, 
he also had painful calf and hand contractures and 
spasms. He denied chest pain, shortness of breath, 
or palpitations. 
Of note, he had been suffering from low calcium 
and low magnesium since starting chemotherapy and 
was on home supplements for both. He had no prior 
history of calcium disorders or any endocrinopathies.  
On physical exam, Trousseau sign was positive with 
use of a blood pressure cuff. He also had hyperreflexia 
in both upper and lower extremities.
Blood work on admission showed an undetect-
able Mg level, a calcium level of 6.0 mg/dL (corrected 
6.6 mg/dL), albumin level of 3.2 mg/dL, and an ionised 
calcium of 0.62 mg/dL. Vitamin D level was normal and 
serum PTH was elevated at 128 pg/mL. 
He was treated with both intravenous magnesium 
and calcium boluses and admitted into the hospital. 
His calcium on discharge was 6.7 g/dL (no correction 
given albumin not measured) with a magnesium level 
of 1.7 mg/dL. He was treated with a total of 10 g of in-
travenous magnesium and 6 g of intravenous calcium 
during his hospital stay. 
The patient was discharged home with oral calcium 
carbonate and oral magnesium oxide. He was scheduled 
to follow up in an oncology clinic in one week to have 
repeat calcium and albumin levels drawn.
Cisplatin is a chemotherapy drug that belongs to the 
platinum-analogues class. It inhibits DNA synthe-
sis. Cisplatin is known for having many adverse effects 
including nephrotoxicity, ototoxicity, and numerous 
electrolyte disturbances, including hypomagnesaemia. 
Magnesium plays an important role in parathyroid 
hormone physiology and calcium homeostasis. Like 
calcium, it is a divalent cation and binds to the calcium 
sensing receptor, subsequently activating it [3, 4].
Cisplatin causes renal tubular damage and necrosis, 
leading to increased renal wasting of magnesium. Ad-
ditionally, it causes damage to calcium and magnesium 
sensing receptors at the level of the thick ascending loop 
of Henle and distal convoluted tubules [1]. Therefore, 
severe hypomagnesaemia that follows leads to both 
parathyroid hormone resistance and decreased secre-
tion from the parathyroid glands.  
The release of PTH from the parathyroid gland 
and the end-organ effect of PTH is based on magne-
sium-dependent Cyclic Adenosine Monophosphate 
(C-AMP) generation which is defective in severe hy-
pomagnesaemia [1]. This leads to decreased calcium 
reabsorption from the kidneys, decreased parathyroid 
hormone-mediated calcium release from bones, and 
decreased vitamin D production leading to decreased 
calcium absorption from the gut [2–4]. 
This can be life threatening. In such patients, calcium 
and magnesium levels need to be monitored very 
closely, and the patients should probably be on oral 
supplements. If this is not possible, then other che-
motherapy regimens should be considered for further 
treatments of such patients. 
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